Drugnews

How much did Novartis’s Entresto sales fall in Q3 2026?

Novartis reported on October 27, 2026 that Entresto generated US$1.165 billion in Q3 2026 sales, down 38% at constant currency, according to Drugnews’s November 3, 2026 analysis. The sacubitril/valsartan brand’s first-nine-month sales were US$3.651 billion, versus US$6.495 billion a year earlier, following U.S. generic entry.

Updated

Entresto sales after U.S. generic entry
MeasureReported resultBasis
Q3 2026 salesUS$1.165 billionWorldwide product sales
Q3 year-over-year decline38%Constant currency
First nine months of 2026US$3.651 billionCumulative sales
Prior-year first nine monthsUS$6.495 billionMatching cumulative period

The quarterly growth rate and the nine-month sales totals cover different periods.

Sources

Read the full analysis

Entresto Sinks 38%; Novartis Bets on Leqvio — 2026-11-03